Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says

Sensei Biotherapeutics (NASDAQ:SNSE) had its target price boosted by Oppenheimer from $3.50 to $4.00 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Sensei Biotherapeutics in a research note on Friday.

Sensei Biotherapeutics Stock Up 18.0 %

SNSE opened at $0.51 on Friday. Sensei Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.94. The company has a 50 day moving average of $0.47 and a two-hundred day moving average of $0.49. The company has a market cap of $12.78 million, a P/E ratio of -0.43 and a beta of 0.16.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.27) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.27). Research analysts anticipate that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd grew its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,903 shares of the company’s stock after acquiring an additional 48,977 shares during the period. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent SEC filing. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.